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Abstract 
This chapter focuses on the anorectic action of the pancreatic hormone amylin and the structurally 
related peptide calcitonin-gene related peptide (CGRP). Both peptides when given peripherally or 
centrally produce potent anorectic effects and delay gastric emptying. The anorectic action of 
CGRP seems to parallel amylin’s effect on eating in many aspects; however, in this chapter, more 
emphasis will be put on the effects of amylin on eating because amylin’s effects may be of 
physiological relevance but this is less clear in the case of CGRP. Other effects of CGRP are 
mentioned in other chapters of this book. 
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Introduction 
The acute and chronic eating inhibitory effects of amylin seem to be one important factor in 
amylin's overall role to control the influx of nutrients into the circulation. Apart from this effect, 
amylin's action to reduce gastric acid secretion, to limit the rate of gastric emptying, and to diminish 
pancreatic glucagon and digestive enzyme secretion are other factors serving the same purpose (12, 
29). Therefore, by regulating nutrient appearance and the postprandial glucose concentration, 
amylin seems to be a necessary and complementary factor to insulin in the control of nutrient flux.  
Amylin, or islet amyloid polypeptide (IAPP), was first isolated from pancreatic amyloid deposits, 
which typically occur in human type 2 diabetes mellitus, in feline diabetes mellitus, and in 
insulinomas in animals and humans. Amylin, however, is also a physiological product of pancreatic 
B-cells from where it is co-secreted with insulin. It is generally assumed that the pancreatic B-cells 
constitute the main source for circulating and postprandially released amylin, and that the increase 
in amylin levels in response to eating is the physiological basis for amylin’s satiating effect. 
Accordingly, pancreatectomized cats have very low baseline amylin (and insulin) levels and 
virtually no postprandial increase in blood amylin levels (unpublished); unfortunately, no measures 
of eating or meal pattern were determined in these studies. 
Eating results in a marked increase in the plasma amylin concentration. This meal-induced increase 
is rapid and correlates with the size of the pertinent meal. Blood levels of CGRP show only a 
modest and late increase in response to eating. Therefore, a physiological role for CGRP in satiation 
appears questionable, at least referring to a hormonal action of circulating CGRP. The source for 
this increase in circulating CGRP may be by spillover from neuronal cells.  
 
Receptors for amylin and CGRP action (9, 13, 24) 
Amylin and CGRP binding sites belong to the family of G-protein coupled receptors. The 
functional amylin receptor involves the calcitonin receptor (CT-R) as a core receptor, whose 
amylin-specificity and affinity is due to the co-expression of one of several receptor activity 
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modifying proteins (RAMPs). The CT-R without co-expression of RAMPs represents the classical 
CT receptor, whereas a typical amylin receptor arises from the interaction of RAMP 1 or RAMP 3 
with the CT-R. A similar principle leads to functional receptors for CGRP; they rely on the co-
expression of the calcitonin receptor-like receptor (CL-R) with appropriate RAMPs. 
Amylin binding sites are widely distributed in the central nervous system and also occur in high 
densities in brain areas involved in the control of eating. The area postrema (AP) which seems to 
mediate amylin’s and CGRP’s effects on eating, contains all components of functional amylin 
receptors, as shown by the presence of RAMP1 and RAMP3 mRNA and positive immunostaining 
for RAMP1, RAMP3 and the CT-R.  
 
Detailed studies of the presence of CL-R protein as part of functional CGRP receptors in the brain, 
and especially in brain areas involved in the control of eating are not available. However, in situ 
hybridization studies have shown that CL-R mRNA is present in the rat brain. Other than in the AP, 
the physiological relevance of amylin and CGRP binding sites for the anorectic actions of amylin 
and CGRP remains unknown. 
 
Characterization of the effects of amylin and CGRP on eating as satiating hormone (12) 
Amylin shares the typical characteristics of satiating hormones which are involved in the control of 
meal size. Amylin is rapidly released during food ingestion, and it dose-dependently reduces meal 
size. Amylin has a rapid onset and brief duration of action, and amylin antagonism increases eating 
by a specific meal size effect (14, 20). 
In contrast to some other satiating hormones like cholecystokinin (CCK), amylin is also active 
under conditions of chronic delivery; amylin reduced eating by decreasing average meal size but it 
may also reduce meal number by increasing the duration of the intermeal interval. Similarly, amylin 
increased the latency to eat under certain experimental conditions. Nonetheless, the best 
characterized function of amylin is the effect to reduce meal size. 
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Qualitatively, CGRP reduces eating by affecting the same meal pattern parameters as amylin; i.e., 
CGRP has also been shown to reduce meal size after acute and chronic administration, and to affect 
the intermeal interval during chronic infusion. Due to the lack of 100% specific antagonists against 
amylin or CGRP receptors and the lack of studies using specific receptor deficient animals, it 
remains unclear whether CGRP’s effects on eating are due to an interaction at amylin receptors or 
due to a specific, amylin independent effect. However, based on its release pattern with an increase 
of plasma CGRP levels only occurring at least 1h after meal onset, it appears unlikely that blood 
borne CGRP constitutes a physiological satiating agent  (7).  
Meal pattern analysis after the injection of amylin or CGRP revealed another potential difference 
between amylin and CGRP action because CGRP reduced the eating rate in rats, at least when using 
higher doses. This suggests that some aversive or illness-producing effect may at least partly 
underlie the anorectic action of CGRP, indicating that its action on feeding is not specific. This 
contrasts with amylin which does not reduce feeding by producing a conditioned taste aversion or 
by an unspecific effect (e.g. via a reduction in drinking)  (12). 
 
The lowest dose of exogenous amylin that produced a significant reduction in feeding yielded 
plasma amylin levels that were about two-times higher than the concentrations measured 
postprandially. Strictly speaking, this means that physiological amylin concentrations that occur at 
the end of spontaneous meals have not yet been shown to reduce feeding. However, different 
kinetics of the blood amylin concentration after exogenous amylin delivery rather than endogenous 
secretion may play a role. Further, under natural feeding conditions many gastrointestinal hormones 
that individually induce satiation are released at the same time and may interact in a way that may 
be difficult to mimic in an experimental setting. Overall, we believe that amylin is a physiological 
control of meal size and that this effect is based on circulating amylin; importantly, several studies 
have clearly shown that peripherally or centrally delivered amylin antagonists produce an effect 
opposite to that of amylin, i.e., an increase in meal size (e.g, (14)).  
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Amylin as an adiposity signal 
The role of amylin as a satiating hormone seems to depend on phasic changes in amylin levels, i.e. 
the meal-induced rise in plasma amylin levels. In addition, amylin may also exert a tonic effect on 
eating, i.e. it may play a role in the long-term control of eating or body weight  (10, 27).  
First, basal levels of amylin also seem to depend on the prevailing body weight and body adiposity, 
in both rats and humans. High-fat fed, obese rats have higher baseline amylin levels than age 
matched lean controls; of note, this does not distinguish between a body weight and a diet effect. 
We recently also investigated whether changes in body adiposity in single individuals are reflected 
in changing amylin levels and whether such changes in adiposity and amylin in fact follow the same 
temporal pattern; rats were rendered overweight by chronic intragastric overfeeding leading to a 
30% excess body weight above normal weight rats. To our surprise, basal amylin levels did not 
change significantly during or after termination of overfeeding. Whether amylin levels may only 
increase after extended periods of overweight or whether the type of diet used during overfeeding 
may play a role is currently unknown. It seems clear that further studies are required to define the 
exact contribution of time, diet, extent of overweight and other potential factors on the obesity 
related increase in plasma amylin levels. 
Second, chronic amylin infusion in rats lowers eating and body weight gain by reducing body 
adiposity while chronic peripheral or central infusion of amylin antagonists increases body weight 
with a major effect on body fat mass while sparing lean body mass (20, 23). We recently showed 
that chronic third ventricular amylin infusions reduce body weight gain in rats irrespective of prior 
weight manipulations. This means that amylin infused rats, whether temporarily food restricted, 
overfed or left unmanipulated, eventually reached similar body weight which was consistently 
lower than in saline infused controls (27). Hence, the effect of a chronic modulation of amylin 
signaling is similar to that of leptin or insulin. The relative contribution of amylin versus leptin or 
insulin to the control of body weight is difficult to judge but it is clear that the lack of leptin in 
ob/ob mice results in a more dramatic obese phenotype than the lack of amylin in amylin deficient 
mice  (8, 12). However, because obesity associated leptin resistance prevents leptin from being 
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effective when the effect apparently would be needed most, additional amylin may be a very 
effective alternative and amylin may play an important modulatory role. Further, even animals with 
defective leptin and insulin signaling (e.g. the Zucker fa/fa rat) keep their body weight relatively 
stable, even though this occurs at a higher level. Hence, amylin may play some role as a adiposity 
feedback signal similar to leptin and insulin, at least when the leptin and insulin feedback signalling 
systems are deficient. 
 
Eating in knockout animals  (16) 
Amylin knockout animals have been developed to study the role of amylin in nutrient and bone 
metabolism  (8). The specific phenotypes of amylin-deficient mice that are not related to amylin’s 
role in the control of eating include a lower bone mass due to a higher number of osteoclasts, and 
reduced late phase nociception in the paw formalin test; the latter implies that endogenous amylin 
increases the perception of chemical pain. 
In the same animals, adult body weight did not differ between knockout and wildtype animals in 
some studies, but amylin knockout mice showed a slightly higher rate of body weight gain 
compared with corresponding wildtype controls; the knockout mice grew significantly faster up to 
about 4 months of age. Eating was slightly though not significantly higher than in control animals  
(12). 
Interestingly, amylin knockout mice also differed from control animals in their interaction with 
other factors controlling eating, indicating that endogenous amylin may have a facilitating role for 
other controls of eating (e.g., CCK  (15); or leptin). Together, these studies suggest a role for 
endogenous amylin in the overall control of energy balance, most likely via an effect on eating and 
in interaction with other satiating and adiposity signals (12). 
 
Eating in amylin receptor knockout animals has not been determined so far. A recent study 
determined the effect of haplodeletion of amylin and its receptor protein (calcitonin receptor; CT-R) 
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on bone metabolism. Heterozygous amylin
+/-
 and heterozygous CT-R
+/-
 mice were crossbred, but 
neither data on eating nor on body weight were reported  (16). 
 
Eating in animals overexpressing amylin  (16) 
To my knowledge, no detailed studies are available on the effect of amylin overexpression on eating 
or body weight. Rats that were transgenic for the overexpression of human amylin gained weight 
comparably until 5 months of age but then had a slightly lower body weight than wild-type controls 
(4). The authors argued that lower body weight may have been a consequence of energy loss due to 
the development of glycosuria and diabetes in the transgenic rats, but no detailed data on eating 
were provided. Hence, reduced eating which in principle would be consistent with the effects of 
exogenous amylin on eating and body weight, cannot be excluded. The rather small difference 
between transgenic and control animals may have been due to receptor desensitization or the 
redundant system controlling body weight. Because the major difference in body weight between 
amylin knockout and wildtype mice occurs during a certain period of life, the same may also hold 
true for animals overexpressing amylin. Another recent paper with mice that were transgenic for the 
overexpression of human amylin did not report data on eating and body weight (28). 
 
Eating in animals deficient of CGRP or overexpressing CGRP  (16) 
While no detailed data are available related to the effect of CGRP overexpression on eating or body 
weight, a recent paper described the effect of genetic CGRP deficiency (CGRP ko) on eating and 
body weight in mice. CGRP ko mice fed different diets ate slightly but significantly more than 
control mice of the same diet group; total eating and eating corrected for body weight gain were 
both increased significantly. This effect on eating in principle is consistent with exogenous CGRP’s 
effect to reduce energy intake.  Surprisingly, however and despite overeating, the ko mice appeared 
to be protected from the development of diet-induced obesity because both their body weight and 
body adiposity were lower than in wildtype animals. The latter effect may be explained by the 
increase in core body temperature and energy expenditure in ko versus wildtype mice  (28). 
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Energy expenditure as affected by amylin and CGRP (reviewed in: (12); see also: (27)) 
A number of studies have shown that acute (central) and chronic amylin administration increase 
energy expenditure as assessed by indirect calorimetry. The effect under chronic conditions may in 
part be secondary to the reduction in adiposity by amylin and hence the relative increase in 
metabolically more active lean body mass. Acute peripheral injection of an anorectic dose of amylin 
failed to increase energy expenditure in rats while the long acting amylin agonist salmon calcitonin 
(sCT) increased it; we therefore believe that this difference may be due to the different biological 
half life of amylin versus sCT. The central neural targets which may mediate the effect of 
exogenous amylin on energy expenditure and the underlying mechanisms are not clear.  
Given the similar eating inhibitory effects of amylin and CGRP, the recent report using CGRP ko 
mice that indicated that the lack of CGRP resulted in increased rather than decreased energy 
expenditure was surprising. Whether CGRP replacement would have corrected for this phenotype 
was not tested  (28). 
 
Energy metabolism in animals with increased amylin or CGRP signaling propensity  (30) 
A recent study provided interesting insight into the potential mechanisms of enhanced amylin or 
CGRP receptor signaling. This study used transgenic mice overexpressing the human RAMP1 gene 
specifically in the central nervous system; because RAMP1 is a chaperone to the amylin (CT-R) 
and CGRP (CL-R) receptors, any effect observed in these mice could be due to enhanced signaling 
of amylin, of CGRP or both. Total eating was reduced temporarily in the transgenic mice, and 
eating related to body weight gain was rather increased. Interestingly, energy expenditure was 
significantly higher in the transgenic mice, probably explaining the lower body weight and 
adiposity. Because the effect of exogenous central amylin but not CGRP on body weight gain was 
markedly enhanced in the transgenic mice, the phenotype of the RAMP1 transgenic mice may be 
mainly due to enhanced brain amylin signaling via the CT-R/RAMP1 receptor complex. This may 
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also explain the apparent paradox between lower body adiposity in these mice, and the effect of the 
knockout of CGRP in mice that resulted in a protection from diet-induced obesity  (28). 
 
Regulation of amylin and CGRP synthesis and secretion in lean and obese individuals (2, 3) 
Due to their co-synthesis and co-localization in secretory vesicles, insulin and amylin are normally 
co-secreted upon activation with the appropriate stimuli; this typically occurs at a fixed ratio of 
about 1:10 to 1:100. Interestingly, divergent secretion of insulin and amylin is possible but it 
remains unclear how differential release of insulin and amylin is regulated. Human obesity, various 
rat models of obesity, diabetes mellitus, pancreatic cancer, and pharmacological intervention (e.g. 
dexamethasone) may lead to relative over-expression and -secretion of amylin versus insulin. Clear 
evidence for a preferential transcription of amylin or increased stability of amylin mRNA under 
these conditions has not been found so far. It has however been hypothesized that differential 
regulation of amylin and insulin mRNA production may involve the cAMP and protein kinase A 
(PKA) pathways, and that different transcription factors for insulin and amylin may be involved. 
 
We recently investigated if obesity or maintenance on a high fat diet (HF diet) affect meal induced 
amylin release in rats. HF fed rats, whether classified as diet-induced obese (DIO) or diet-resistant 
(DR) exhibited an earlier meal-induced rise in amylin compared to lean chow-fed controls. Further, 
DR rats had higher amylin:insulin ratios before and after a meal. In principle, these findings are 
consistent with the demonstration that elevated fatty acids, which can result from the consumption 
of a diet high in fat, induce enhanced mRNA expression and release of amylin, but not insulin. One 
important overall conclusion from these experiments in respect to amylin’s role in the control of 
eating and in obesity was that amylin secretion does not seem to be blunted in obesity; it therefore 
seems unlikely that insufficient release of amylin contributes to overeating in obesity or in 
individuals on HF diets. 
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Obese individuals have been reported to have higher CGRP levels than lean controls  (7), but the 
physiological relevance of this finding is unclear. A direct link between baseline CGRP levels and 
the degree of adiposity appeared unlikely because CGRP did not decrease in response to body 
weight loss. Plasma levels of CGRP increase in response to eating mainly by spillover from sensory 
nerve endings rather than controlled release from endocrine cells. This was only seen after a 
highfat, but not after a high carbohydrate meal, and the late increase (> 1h) argues against an effect 
of CGRP on individual meals. Specific studies directly comparing the meal induced changes in 
CGRP secretion and blood concentrations in lean versus obese individuals or in individuals on 
specific diets have not been reported. 
 
Central pathways mediating the anorectic effects of amylin and CGRP (reviewed in: (12, 17)) 
Experimental evidence supports the idea that the anorectic effect of peripheral amylin is mediated 
by direct humoral action on the area postrema (AP) in the hindbrain. Amylin binding sites have 
been described in various CNS locations involved in the control of eating, but behavioral tests with 
peripheral or local AP infusions, immunohistological and electrophysiological experiments all 
indicate that the AP seems to be necessary as primary site of action for peripheral amylin to reduce 
eating.  
Blood borne amylin has easy access to AP neurons due to the lack of a functional blood brain 
barrier in this area; several studies from different laboratories have shown that peripheral amylin’s 
anorectic action is abolished in rats with lesions in the AP. Endogenous blood borne amylin also 
appears to act via the AP because an infusion of the amylin antagonist AC 187 into the AP 
increased eating due to an increase in meal size; further, AC 187 infused into the AP also partly 
blocked the anorectic effect induced by a peripheral amylin injection, providing the best in vivo 
evidence for the importance of the AP in mediating peripheral amylin’s anorectic action. 
Electrophysiological and immunohistochemical studies indicate that AP neurons are directly and 
dose-dependently stimulated by amylin, and that exogenous and endogenous amylin produced a 
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strong expression of the immediate early gene product c-Fos protein as a marker of neuronal 
activation in AP neurons. Both responses were effectively blocked by AC 187.  
 
Phenotype of amylin responsive neurons in the AP (19) 
Expression of c-Fos protein was used to determine the phenotype of amylin responsive neurons in 
the AP. We found that about 50% of amylin-activated AP neurons are noradrenergic because they 
expressed dopamine-beta-hydroxylase (DBH), the enzyme catalyzing noradrenaline (NA) synthesis. 
These neurons seem to play a specific functional role in amylin’s effect on eating because even a 
partial (approx. 50%) lesion of the NA-containing neurons in the AP was sufficient to block the 
acute eating effect of peripheral amylin. Further, amylin did not induce a significant c-Fos response 
in AP neurons in NA-lesioned rats.  
 
Intracellular signaling pathways in AP neurons activated by amylin (12, 17) 
We believe that the amylin induced c-Fos response in the AP has no functional implications 
because the kinetics of c-Fos expression and the onset of amylin’s anorectic effect are inconsistent. 
We recently provided evidence for a functional role of phosphorylation of the extracellular signal 
regulated kinase (pERK1/2) cascade in amylin’s effect; amylin induced ERK1/2 phosphorylation, 
and (partial) blockade of this effect attenuated amylin’s feeding response. How this relates 
functionally to amylin induced cGMP formation in AP neurons remains to be investigated. 
 
Projections of AP neurons implicated in amylin’s and CGRP’s effects and hypothalamic 
involvement in the anorectic action of peripheral amylin  (18, 21) 
Amylin elicits a strong c-Fos response in AP projection areas, namely the nucleus of the solitary 
tract (NTS), the lateral parabrachial nucleus (lPBN), the central nucleus of the amygdala (CeNA), 
and the bed nucleus of the stria terminalis (BNST). The AP, NTS, and the lPBN form a necessary 
part of the CNS pathway conveying amylin's anorectic signal to higher brain structures; their 
activation seems to be secondary to an action of amylin on AP neurons.  
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Retrograde and anterograde tracer studies confirmed reciprocal projections between these amylin 
activated areas. We identified dense projections from the amylin activated neurons in the lPBN and 
sparse projections from the NTS to the dorsal lateral hypothalamus (dLHA) where amylin reduces 
fasting induced c-Fos expression; hence, the lPBN may thus mediate the amylin-induced inhibition 
of the dLHA. This inhibition may be linked to the down-regulation of the expression of orexin and 
melanin-concentrating hormone in the dLHA.  
Dense efferents were also observed from the lPBN to other hypothalamic areas, namely to the 
ventromedial (VMH), dorsomedial, paraventricular (PVN) and arcuate nuclei (ARC). Their 
functional role is not entire clear, but see paragraphs on amylin/leptin interactions and the role of 
the ventromedial hypothalamus in this respect. 
 
Site of CGRP action 
The site of action for CGRP’s anorectic action has been investigated in less detail than that of 
amylin. Similar to amylin, the anorectic action of peripheral CGRP is abolished in rats with an AP 
lesion. Immunohistochemical and electrophysiological studies have not been performed to the same 
extent as for amylin, so that it is difficult to integrate these findings into the whole brain network for 
the physiological control of eating.  
 
Forebrain effects of amylin (12) 
The role of forebrain amylin receptors is still unclear. It seems likely that these receptors mediate 
the anorectic action of amylin infused into the third brain ventricle; this effect is very potent and 
long-lasting, and third ventricular infusion of AC 187 increases eating in rats. The latter is 
associated with an increase in body weight and the weight of the retroperitoneal fat pads. 
Nonetheless, the functional relevance of these findings under physiological conditions is not clear 
and at present there is no evidence to suggest that forebrain amylin receptors are involved in the 
regulation of eating by peripheral amylin.  
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CNS production of amylin has not been shown unequivocally, except in a recent interesting study 
pointing to a potential role of hypothalamic amylin in the modulation of maternal behavior  (6). The 
physiological relevance of these findings is currently under investigation. 
 
Forebrain effects of CGRP 
Injection of CGRP into the PVN which contains CGRP binding sites (5) produced a strong 
anorectic effect, and it increased the concentration of various anorectic neuropeptides in the 
hypothalamus. However, the physiological relevance of these findings is unclear because very high 
doses of CGRP had been used, exceeding the EC50 for amylin to elicit an anorectic effect after 
administration into the third brain ventricle by a factor of more than 200. Further, the PVN content 
of CGRP was elevated in response to fasting, which is difficult to reconcile with the idea of CGRP 
acting as an anorectic hormone or neuropeptide. Hence, the role of CGRP as a brain-intrinsic 
neuropeptide in the control of feeding remains to be investigated.  
 
Interaction between amylin and estradiol (11, 25) 
Only few studies tested the specific anorectic effect of amylin in females. Similar to CCK and other 
satiating hormones, single acute injections of amylin were more effective in ovariectomized rats 
with physiological estradiol replacement than in rats without replacement. Further, the amylin 
antagonist AC187 increased eating more in estradiol replaced ovariectomized animals, pointing to 
the physiological relevance of the modulating effect of estradiol on amylin action. Surprisingly, the 
effect was opposite under chronic conditions; in other words, the action of chronic amylin on eating 
and body weight was stronger in ovariectomized rats that lacked estradiol than in control rats or in 
ovariectomized rats receiving estradiol replacement. Chronic amylin also at least partly restored the 
metabolic rate that was decreased as a consequence of ovariectomy. Hence, the interaction between 
amylin and estradiol seems to be complex and these apparently opposing phenomena require 
intensified studies. 
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Short-term interaction with other hormones controlling ingestive behavior (12, 22) 
Subthreshold doses of peripheral insulin and amylin reduce eating in rats when co-administered, 
and central insulin enhanced the action of peripheral amylin. Further, amylin and CCK also seem to 
interact in their effect on eating. CCK and amylin synergistically reduced eating; similar synergistic 
effects have been reported with PYY and for the combination of sCT with the GLP-1 agonist 
exendin-4 in non-human primates  (1). Further, part of the satiating action of CCK seems to be 
mediated by amylin, because amylin antagonists attenuated CCK’s anorectic actions in rats and 
because the anorectic effect of CCK was almost abolished in amylin knockout mice; the latter effect 
was restored by amylin. In other words, endogenous amylin seems to modulate CCK's anorectic 
effect.  
 
Interaction between amylin and leptin (22, 26) 
Amylin and leptin seem to interact acutely and chronically. Acute central leptin increased the 
eating-inhibitory effect of peripheral amylin. Further, two-week peripheral infusions of amylin and 
leptin were performed in leptin resistant DIO rats. Amylin alone reduced eating and led to a 
decrease in body weight. Interestingly, rats pair fed to the amylin group and that received leptin did 
not lose more weight than amylin-treated rats. However, combined application of exogenous leptin 
and amylin decreased eating and body weight more than amylin alone, and body fat was lowest 
after leptin/amylin. Hence, amylin strongly enhanced the sensitivity of obese rats to the catabolic 
effect of leptin, including an increase in energy expenditure. Body fat loss was more in the 
amylin/leptin treated rats than in the pair-fed controls; this was consistent with a lower respiratory 
quotient, indicating preferential fat oxidation. One important point to consider is that the 
interactions of amylin and leptin on eating and adiposity have mainly been shown under 
pharmacological, not under physiological conditions. 
 
Role of the VMH in the leptin and amylin interaction (26) 
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The interaction between amylin and leptin appears to be due to a direct effect of amylin on central 
leptin signalling, most likely in the VMH and potentially the hypothalamic ARC. Amylin enhanced 
leptin signalling as gauged by increased immunoreactivity of pSTAT3 specifically in the VMH; this 
effect may be linked to an amylin-induced upregulation of leptin receptor expression and hence 
direct enhancement of leptin action in VMH neurons. Further, amylin deficient mice had a reduced 
leptin receptor expression in the mediobasal hypothalamus.  
 
Interaction between amylin and metabolites  (12) 
Higher doses of amylin are necessary to inhibit sham feeding than real feeding which may be due to 
the lack of cooperative effects between amylin and metabolites (e.g., elevated glucose) under these 
conditions. Similar to amylin’s effect on gastric emptying, amylin’s eating inhibitory effect seems 
to be reduced in rats with induced hypoglycemia. This is in line with coactivation of AP neurons by 
physiological concentrations of amylin and glucose. The co-responsiveness of AP neurons to 
amylin and glucose is similar to that for glucose and CCK; AP neurons may therefore integrate 
metabolic and hormonal signals that control eating. 
 
Physiological and pathophysiological implications 
Relatively little is known about the possible role of amylin's effect on feeding under 
pathophysiological conditions. It has been hypothesized that amylin may contribute to cancer 
anorexia in certain pancreatic neoplasia which may be associated with chronically 
supraphysiological plasma amylin levels.  
An altered ratio between amylin and insulin has been supposed to play a role in eating disorders and 
hence to contribute to abnormal feeding behavior in diabetes mellitus. In other words, the lack of 
amylin in type 1 diabetes and later stages of type 2 diabetes could result in increased eating or body 
weight. The clinical experience with the amylin analogue pramlintide in the treatment of type 1 and 
2 diabetes is consistent with this idea. Individuals treated with pramlintide plus insulin lost body 
weight while patients treated with insulin alone gained weight. Subsequent trials showed that 
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pramlintide decreased in eating and body weight in obese or diabetic patients. Because obesity and 
chronic hyperamylinemia, which is typically associated with obesity, do not seem to reduce amylin 
effectiveness, amylin may be a promising and potent approach to treat obese patients. Similar to the 
data in rats, this effect can be potentiated when amylin is combined with leptin.  
Similar data are not available for CGRP. Hence, it is unknown whether CGRP or CGRP analogues 
produce similar or even more potent effects than amylin in a clinical setting. Given the current 
availability of data, amylin seems to be a more promising and safer approach than CGRP. 
 
Summary 
Both amylin and the structurally related neuropeptide CGRP reduce eating. While amylin may be a 
physiological control of meal size, this is less clear for CGRP. The effects of peripheral amylin and 
CGRP on eating are centrally mediated by the AP in the hindbrain as the most likely primary target 
area. Chronic exposure to amylin decreases eating and body weight gain. Next to a satiating action, 
amylin may also constitute an adiposity feedback signal. The anorectic action of amylin is 
pharmacologically exploited because amylin analogs are under clinical consideration for their effect 
to reduce eating and body weight in humans; this effect can be potentiated with leptin co-therapy. 
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